April 30 (Reuters) - CSL Ltd (CSL) :
- ARS PHARMACEUTICALS SUBMITS RESPONSE FOR NEFFY® (EPINEPHRINE NASAL SPRAY) MARKETING AUTHORIZATION APPLICATION TO EMA’S CHMP AND ENTERS LICENSE AGREEMENT WITH CSL SEQIRUS FOR COMMERCIALIZATION OF NEFFY IN AUSTRALIA AND NEW ZEALAND
- ARS PHARMACEUTICALS INC: CHMP OPINION ON NEFFY MARKETING AUTHORIZATION APPLICATION ANTICIPATED IN Q2 OF 2024
News: CSL ARS Pharmaceuticals CHMP Opinion On Neffy Marketing Authorization Application Expected In...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$253.45 |
Change
-3.930(1.53%) |
Mkt cap ! $123.1B | |||
| Open | High | Low | Value | Volume |
| $256.32 | $256.50 | $252.60 | $34.36M | 135.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 60 | $253.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $253.45 | 42 | 6 |
View Market Depth
| Last trade - 11.23am 21/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |